Drugs / ARGX-109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06799416 | Jan → Aug 2025 | — | argenx | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-10-03 | argenx | RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody argenx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARGX-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799416 ↗ |
| Route | Subcutaneous | “ARGX-109 Administered Subcutaneously in Healthy Adult Participants” NCT06799416 ↗ |